Search over 3,000 reports

    Atopic Dermatitis (AD) - Market Insights, Epidemiology and Market Forecast - 2025

    Atopic Dermatitis (AD) - Market Insights, Epidemiology and Market Forecast - 2025
    Date: Sep, 2017
    Type:
    Pages: 144
    Geography: Global
    Delivery Timeline: 24 Hours
    SKU: DIMI0253

    DelveInsight's 'Atopic Dermatitis - Market Insights, Epidemiology and Market Forecast-2025' report provides an overview of Atopic Dermatitis, epidemiology and market trend of Atopic Dermatitis for the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.
    The Report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Atopic Dermatitis from 2017 to 2025 segmented by seven major markets. In addition, the report also includes the forecasted epidemiology of Atopic Dermatitis till 2025. The Report also covers market drivers, market barriers and unmet medical need.


    Our report provides the subtype specific prevalent population i.e., Mild Atopic Dermatitis, Moderate Atopic Dermatitis and Severe Atopic Dermatitis.  According to DelveInsight, the prevalent population of Atopic Dermatitis is expected to reach up to XXX cases by the end of 2025 at a CAGR of XX% from 2015-2025. High prevalent cases were observed in United States as compared to EU5 and Japan.

    Market is driven by various approved drugs for Atopic Dermatitis such as Elidel (Novartis), Protopic (Fujisawa Healthcare) and Desonate (Bayer Healthcare). There has been a positive impact on the market with the approval of Eucrisa (Pfizer) and Dupilumab (Regeneron Pharmaceuticals/Sanofi) in 2016 and 2017 respectively.
    United States contributes the major share of Atopic Dermatitis market as compared to EU5 countries and Japan. The therapeutic market of Atopic Dermatitis in 7MM is expected to reach USD XXX Million in 2025 at the CAGR of XX% from 2015-2025. 

    Key Coverage and Benefits:

    • The report will help in developing business strategies by understanding the trends shaping and driving the Atopic Dermatitis market.
    • The Report provides detailed historical and forecasted epidemiological data of Atopic Dermatitis in the 7MM i.e., United States, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025. 
    • Organize sales and marketing efforts by identifying the best opportunities for Atopic Dermatitis in US, Europe (Germany, Spain, Italy, France and United Kingdom) and Japan. 
    • To understand the future market competition in the Atopic Dermatitis market and insightful review of the key market drivers and barriers.
    • To understand the regulatory scenario in major markets.
    • The Report covers the detailed historical and forecasted Atopic Dermatitis market covering the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

    1. Report Introduction 
    2. Atopic Dermatitis Market Overview at a Glance 
    2.1. Market Share Distribution of Atopic Dermatitis in 2016 
    2.2. Market Share Distribution of Atopic Dermatitis in 2025 
    3. Disease Background and Overview 
    3.1. Etiology 
    3.2. Risk Factors 
    3.3. Pathophysiology 
    3.3.1. Mediators involved in Pathophysiology 
    3.3.2. Major Mediators for inducing atopic Dermatitis 
    3.3.3. Emphasis on development of Phosphodiesterase-4 inhibitors 
    3.3.4. Other Mediators 
    3.3.5. Potential targets for antipruritic therapy in AD 
    3.3.6. Triggering factors involved in pathophysiology 
    3.4. Diagnosis 
    3.5. American Academy of Dermatology Diagnostic Criteria 
    3.6. United Kingdom Working Party Diagnostic criteria 
    3.7. Japanese Dermatological Association Diagnostic Criteria 
    4. Epidemiology and Patient Population 
    4.1. Disease Definition 
    4.2. Population and Forecast Parameters 
    4.3. Population Methods 
    4.3.1. Total prevalent cases in US 
    4.3.2. EU5 
    4.3.3. Japan 
    4.4. Prevalent Population of Atopic Dermatitis in 7MM 
    4.5. Prevalent Population of Atopic Dermatitis by Severity in 7MM 
    4.6. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in 7MM 
    4.6.1. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in the United States 
    4.6.2. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in Germany 
    4.6.3. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in France 
    4.6.4. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in Italy 
    4.6.5. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in Spain 
    4.6.6. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in United Kingdom 
    4.6.7. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in Japan 
    4.7. Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases in 7MM 
    4.8. Prevalent Cases with Uncontrolled Atopic Dermatitis in 7MM 
    4.9. Prevalent Cases with Uncontrolled Atopic Dermatitis in Children and Adults in 7MM 
    5. Treatment Practices 
    6. Treatment Algorithm 
    6.1. Treatment Goals 
    6.2. First Line of Treatment 
    6.3. Second Line of Treatment 
    7. Treatment Failure 
    8. Treatment by class 
    8.1. Topical Therapies 
    8.2. Systemic therapies 
    8.3. Approved Drugs for Atopic Dermatitis 
    9. Emerging Therapies 
    10. Nemolizumab: Galderma Pharma 
    10.1. Product Description 
    10.2. Research and Development 
    10.3. Product Development Activities 
    11. Tralokinumab: LEO Pharma 
    11.1. Product Description 
    11.2. Research and Development 
    11.3. Product Development Activities 
    12. Tradipitant: Vanda Pharmaceuticals 
    12.1. Product Description 
    12.2. Research and Development 
    12.3. Product Development Activities 
    13. ZPL-389: Novartis 
    13.1. Product Description 
    13.2. Research and Development 
    13.3. Product Development Activities 
    14. NST-141: Nippon Shinyaku 
    14.1. Product Description 
    14.2. Research and Development 
    14.3. Product Development Activities 
    15. Serlopitant: Menlo Therapeutics 
    15.1. Product Description 
    15.2. Research and Development 
    15.3. Product Development Activities 
    16. DS107: DS Biopharma 
    16.1. Product Description 
    16.2. Research and Development 
    16.3. Product Development Activities 
    17. Asimadoline: Tioga Pharmaceuticals 
    17.1. Product Description 
    17.2. Research and Development 
    17.3. Product Development Activities 
    18. GSK2894512:  GlaxoSmithKline 
    18.1. Product Description 
    18.2. Research Development Activities 
    18.3. Product Development Activities 
    19. Lebrikizumab: Roche 
    19.1. Product Description 
    19.2. Research and Development 
    20. DMT210: Dermata Therapeutics 
    20.1. Product Description 
    20.2. Research and Development 
    20.3. Product Development Activities 
    21. SNA-120: Sienna Biopharmaceutical 
    21.1. Product Description 
    21.2. Research and Development 
    21.3. Product Development Activities 
    22. RVT-501: Roivant Sciences 
    22.1. Product Description 
    22.2. Research and Development 
    22.3. Product Development Activities 
    23. OPA-15406: Otsuka Pharmaceutical 
    23.1. Product Description 
    23.2. Research and Development 
    23.3. Product Development Activities 
    24. Current Unmet Need 
    25. Atopic Dermatitis: Market Analysis 
    25.1. Market Outlook 
    25.2. Market size of Atopic Dermatitis in 7MM 
    25.3. Market analysis of Atopic Dermatitis in 7MM 
    26. Atopic Dermatitis: United States Market Outlook 
    26.1. Market size 
    27. Atopic Dermatitis: EU5 
    28. Market Outlook 
    28.1. Germany Market size 
    28.2. France Market size 
    28.3. Italy Market size 
    28.4. Spain Market size 
    28.5. United Kingdom Market size 
    29. Atopic Dermatitis: Japan Market Outlook 
    29.1. Japan Market size 
    30. Market Drivers 
    31. Market Barriers 
    32. Expert Opinions 
    32.1. Views on Current treatment options 
    32.2. Views on emerging therapies 
    33. Appendix 
    33.1. Report Methodology 
    33.2. Consulting Services 
    33.3. Disclaimer 
    33.4. About DelveInsight 

     

    Table 1:Mediators of itch in atopic dermatitis by their role in provocation of itch
    Table 2: Targets focused by companies
    Table 3: Concept of Atopic Dermatitis by Wise and Sulzberger
    Table 4: Hanifin and Rajka Diagnostic Criteria
    Table 5: American Academy of Dermatology Diagnostic Criteria
    Table 6: United Kingdom Working Party diagnostic criteria
    Table 7: Japanese Dermatological Association Diagnostic Criteria
    Table 8: Total Prevalent Population of Atopic Dermatitis in 7 MM (2015-2025)
    Table 9: Total Prevalent Population of Atopic Dermatitis by Pruritus Burden in 7 MM (2015-2025)
    Table 10: Prevalent Population of Atopic Dermatitis by Pruritus Burden in United States (2015-2025)
    Table 11: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Germany (2015-2025)
    Table 12: Prevalent Population of Atopic Dermatitis by Pruritus Burden in France (2015-2025)
    Table 13: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Italy (2015-2025)
    Table 14: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Spain (2015-2025)
    Table 15: Prevalent Population of Atopic Dermatitis by Pruritus Burden in UK (2015-2025)
    Table 16: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Japan (2015-2025)
    Table 17: Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases in 7MM (2015-2025)
    Table 18: Total Prevalent Population with Uncontrolled Atopic Dermatitis in 7 MM (2015-2025)
    Table 19:Total Prevalent Population with Uncontrolled Atopic Dermatitis in Children and Adults in 7 MM (2015-2025)
    Table 20: Reasons for noncompliance with medication
    Table 21: Topical corticosteroids
    Table 22: Topical Calcineurin Inhibitors (TCIs)
    Table 23: Topical Phosphodiesterase Type-4 (PDE4) inhibitors
    Table 24: Oral Corticosteroids
    Table 25: Biologic medications
    Table 26: Systemic Immunomodulating agents
    Table 27: Emerging therapies
    Table 28: 7 Major Market  Size of Atopic Dermatitis in USD Million (2015-2025)
    Table 29: 7 Major Market  Analysis of Atopic Dermatitis in USD Million (2015-2025)
    Table 30: Market  Size of Atopic Dermatitis in United States, USD Millions  (2015-2025)
    Table 31: Market  Size of Atopic Dermatitis in Germany , USD Million (2015-2025)
    Table 32: Market  Size of Atopic Dermatitis in France, USD Million (2015-2025)
    Table 33: Market  Size of Atopic Dermatitis in Italy, USD Million (2015-2025)
    Table 34: Market  Size of Atopic Dermatitis in Spain , USD Million (2015-2025)
    Table 35: Market  Size of Atopic Dermatitis in United Kingdom, USD Million (2015-2025)
    Table 36:Market  Size of Atopic Dermatitis in Japan , USD Million (2015-2025)

     

    Figure 1: Risk Factors for Atopic Dermatitis
    Figure 2: Pathophysiology of Atopic Dermatitis
    Figure 3: Mediators involved in Pathophysiology of Atopic Dermatitis
    Figure 4: Mediators with their mechanism of action in inducing Atopic Dermatitis
    Figure 5: Triggering factors involved in pathophysiology of Atopic Dermatitis
    Figure 6: Total Prevalent Population of Atopic Dermatitis in 7 MM (2015-2025)
    Figure 7: Total Prevalent Population of Atopic Dermatitis by Severity in 7 MM (2015-2025)
    Figure 8: Total Prevalent Population of Atopic Dermatitis by Pruritus Burden in 7 MM (2015-2025)
    Figure 9: Prevalent Population of Atopic Dermatitis by Pruritus Burden in United States (2015-2025)
    Figure 10: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Germany (2015-2025)
    Figure 11: Prevalent Population of Atopic Dermatitis by Pruritus Burden in France (2015-2025)
    Figure 12: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Italy (2015-2025)
    Figure 13: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Spain (2015-2025)
    Figure 14: Prevalent Population of Atopic Dermatitis by Pruritus Burden in UK (2015-2025)
    Figure 15: Prevalent Population of Atopic Dermatitis by Pruritus Burden in Japan (2015-2025)
    Figure 16: Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases in 7MM (2015-2025)
    Figure 17: Total Prevalent Population with Uncontrolled Atopic Dermatitis in 7 MM (2015-2025)
    Figure 18:Total Prevalent Population with Uncontrolled Atopic Dermatitis in Children and Adults in 7 MM (2015-2025)
    Figure 19: General Treatment for Atopic Dermatitis
    Figure 20: First Line of treatment for Atopic Dermatitis
    Figure 21: Second Line of treatment for Atopic Dermatitis
    Figure 22: Current Unmet Need for Atopic Dermatitis
    Figure 23: 7 Major Market  Size of Atopic Dermatitis in USD Million (2015-2025)
    Figure 24: 7 Major Market  Analysis of Atopic Dermatitis in USD Million (2015-2025)
    Figure 25: Market  Size of Atopic Dermatitis in United States, USD Millions  (2015-2025)
    Figure 26: Market  Size of Atopic Dermatitis in Germany , USD Million (2015-2025)
    Figure 27: Market  Size of Atopic Dermatitis in France, USD Million (2015-2025)
    Figure 28: Market  Size of Atopic Dermatitis in Italy, USD Million (2015-2025)
    Figure 29: Market  Size of Atopic Dermatitis in Spain, USD Million (2015-2025)
    Figure 30: Market  Size of Atopic Dermatitis in United Kingdom , USD Million (2015-2025)
    Figure 31:Market  Size of Atopic Dermatitis in Japan , USD Million (2015-2025)

     

    Regeneron Pharmaceuticals
    Pfizer
    Bayer Healthcare
    Connetics Corporation
    Novartis
    Fujisawa Healthcare
    Aventis Pharma
    Leo Pharma
    Roche
    Dermata Therapeutics
    Otsuka Pharmaceutica
    And others..
    • Single User Price
      $5,750.00
    • Site License Price
      $11,500.00
    • Enterprise Price
      $17,250.00

    Contact Us

    Phone
    +91-11-45689769, +91 9650213330

    Email
    info@delveinsight.com

    Address
    New Delhi-110075, India

    Latest Tweets

    • Copyright © 2017 Delveinsight.
    • Sitemap